Moreover, plasma kallistatin levels are markedly reduced in animal models of hypertension, STZ-induced diabetes mellitus, lipopolysaccharide- (LPS-) induced endotoxemia, renal injury, and hepatocellular carcinoma [15, 18, 29, 40–42]. Here, SERPINA4 is linked to diabetes mellitus.